Study Title: A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado Trastuzumab Emtansine For Recurrent, Metastatic or Treatment Naïve, Unresectable HER-2 Positive Salivary Gland Cancer
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Kaczmar, John, at kaczmar@musc.edu, or please call +1 843-792-6691.Study Coordinator, Avinger, Madison, at avingerm@musc.edu.Trial opened at the following institutions: Medical University of South Carolina